TuHURA Biosciences, Inc./NV HURA
We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to "trick" the body's immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naïve utilizing the FDA's accelerated approval pathway.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | — | — | — | — | — | — |
| R&D | $20.5M | $13.3M | $9.4M | $15.2M | $11.8M | $3.6M | $3.7M | -$7.1M | $5.0M | $3.4M |
| SG&A | $7.6M | $3.9M | $4.1M | $7.5M | $9.8M | $4.5M | $4.7M | -$4.0M | $3.3M | $2.9M |
| Total operating expenses | $31.8M | $17.6M | $29.8M | $22.7M | $38.2M | -$9.2M | $8.4M | -$11.2M | $8.3M | $6.2M |
| Interest expense | $625.3K | $4.1M | $18.7K | — | $30.0K | — | — | — | — | — |
| Pre-tax income | -$30.1M | -$21.7M | $29.3M | — | — | — | — | — | — | — |
| Income tax | $1.6K | $3.8K | $0 | — | — | — | — | — | — | — |
| Net income | -$31.0M | -$23.0M | -$15.0M | -$22.7M | -$38.3M | -$9.1M | -$8.0M | $11.1M | -$8.1M | $8.9M |
| EPS, basic | -0.63 | -1.21 | -2.47 | -25.80 | -1.60 | -0.87 | 3.16 | 5.42 | 7.36 | 0.83 |
| EPS, diluted | -0.63 | -1.21 | -2.47 | — | — | — | — | — | — | — |
| Shares, diluted (wtd. avg.) | 47.9M | 18.7M | 11.9M | 974,000 | 25.9M | 10.4M | 2.6M | 2.1M | 1.2M | 10.9M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.6M | $12.7M | $3.7M | $14.3M | $10.5M | $2.4M | $3.7M | $6.0M | $6.6M | $6.2M |
| Total current assets | $4.6M | $19.6M | $4.2M | $13.3M | $11.8M | $2.9M | $4.0M | $7.0M | $7.9M | $6.3M |
| Property, plant and equipment | $300.6K | $123.4K | $182.2K | $90.0K | $150.0K | $2.0K | — | — | — | — |
| Goodwill | $10.7M | — | — | — | — | — | — | — | — | — |
| Other intangibles | — | — | — | — | — | $2.1K | $12.1K | $28.4K | $40.3K | $36.0K |
| Total assets | $27.4M | $20.0M | $4.4M | $15.9M | $13.5M | $2.9M | $4.0M | $7.1M | $7.9M | $6.4M |
| Accounts payable | $3.8M | $3.2M | $1.9M | $3.3M | $2.2M | $2.0M | $1.7M | $1.5M | $1.2M | $584.0K |
| Short-term debt | — | — | — | — | — | — | — | — | $33.1K | — |
| Total current liabilities | $5.9M | $5.3M | $3.6M | $4.0M | $2.8M | $2.7M | $2.1M | $1.6M | $1.3M | $627.4K |
| Long-term debt | — | — | — | — | — | — | — | $1.1K | $28.1K | $693.7K |
| Total liabilities | $6.4M | $5.4M | $5.9M | $4.2M | $3.0M | $2.7M | $2.1M | $1.6M | $1.3M | $1.5M |
| Retained earnings | -$141.2M | -$111.1M | -$88.5M | -$136.4M | -$111.2M | -$69.7M | -$60.6M | -$52.4M | -$41.1M | -$32.2M |
| Total equity | $20.9M | $14.6M | -$1.6M | $12.3M | $10.6M | $263.0K | $2.0M | $5.4M | $6.6M | $4.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.6M | -$14.7M | -$12.0M | -$20.4M | -$18.9M | -$7.9M | -$6.3M | -$9.9M | -$8.0M | -$5.1M |
| Depreciation and amortisation | $71.3K | $116.7K | $177.4K | $60.0K | $30.0K | — | — | — | — | — |
| Stock-based compensation | $6.4M | $2.0M | $478.9K | — | — | — | $426.0K | $495.9K | $124.7K | $394.1K |
| Capital expenditure | $76.1K | $57.9K | $79.2K | — | — | — | — | — | — | — |
| Investing cash flow | -$1.3M | -$6.1M | -$1.3M | — | $964.0K | — | — | -$12.6K | -$21.0K | -$16.8K |
| Financing cash flow | $19.9M | $29.8M | $2.7M | $21.6M | $26.0M | $6.6M | $4.1M | $9.2M | $8.5M | $9.6M |
| Buybacks | — | — | $24.8K | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-299680.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $8.9M | -$8.1M | $11.1M | -$8.0M | -$9.1M | -$38.3M | -$22.7M | -$15.0M | -$23.0M | -$31.0M |
Recent filings and events
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- New debt or obligation Item 2.03
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- New debt or obligation Item 2.03
- New debt or obligation Item 2.03
- New debt or obligation Item 2.03
- Director nominations Dates and mechanics for shareholders proposing directors. Item 5.08
- New debt or obligation Item 2.03
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |